Skip to main content
. 2020 Sep 18;15(9):e0239329. doi: 10.1371/journal.pone.0239329

Fig 5. Testing of selected RDs across Euro-NMD consortium centres providing unique EUGT number.

Fig 5

For each disease, the percentage of centres offering diagnosis, distribution of centres across European countries and technologies used are reported. a) SMN genes testing; b) DMD gene testing; c) LGMDs genes (SGCs: Sarcoglycan α, β, γ; CAPN3: Calpain3,DYSF: dysferlin; ANO5: anoctamin 5);d) GAA gene; e) TTR gene testing.